Xencor

Xencor company information, Employees & Contact Information

Explore related pages

Related company profiles:

Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Looking for a particular Xencor employee's phone or email?

Xencor Questions

News

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Yahoo Finance

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Yahoo Finance

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - FinancialContent

Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma FinancialContent

Xencor to Participate at Upcoming Investor Conferences - Business Wire

Xencor to Participate at Upcoming Investor Conferences Business Wire

Xencor Reports Second Quarter 2025 Financial Results - Business Wire

Xencor Reports Second Quarter 2025 Financial Results Business Wire

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates - PR Newswire

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates PR Newswire

Xencor Appoints Todd Simpson to Board of Directors - Yahoo Finance

Xencor Appoints Todd Simpson to Board of Directors Yahoo Finance

Xencor axes its pipeline lead | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Xencor axes its pipeline lead | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Engineered antibody Fc variants with enhanced effector function - PNAS

Engineered antibody Fc variants with enhanced effector function PNAS

Biopharmaceutical Tech Company Xencor to Officially Open 30,600 Square Feet Laboratory in Pasadena Wednesday - Pasadena Now

Biopharmaceutical Tech Company Xencor to Officially Open 30,600 Square Feet Laboratory in Pasadena Wednesday Pasadena Now

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors - Business Wire

Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors Business Wire

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies - PR Newswire

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies PR Newswire

Xencor Reports First Quarter 2025 Financial Results - Business Wire

Xencor Reports First Quarter 2025 Financial Results Business Wire

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease - Business Wire

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease Business Wire

Xencor Announces Proposed Public Offering of Common Stock - Business Wire

Xencor Announces Proposed Public Offering of Common Stock Business Wire

Xencor Announces Pricing of $175 Million Public Offering of Common Stock - Business Wire

Xencor Announces Pricing of $175 Million Public Offering of Common Stock Business Wire

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs - Business Wire

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs Business Wire

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor - Business Wire

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Business Wire

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release - Seeking Alpha

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release Seeking Alpha

MD Anderson and Xencor collaborate to develop bispecific antibody therapies for cancer - MD Anderson Cancer Center

MD Anderson and Xencor collaborate to develop bispecific antibody therapies for cancer MD Anderson Cancer Center

Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer - Business Wire

Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer Business Wire

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab - Business Wire

Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab Business Wire

Xencor to Present at the 42nd Annual JP Morgan Healthcare Conference - FinancialContent

Xencor to Present at the 42nd Annual JP Morgan Healthcare Conference FinancialContent

Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech - PR Newswire

Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech PR Newswire

Xencor unveils new programs targeting autoimmune and inflammatory diseases - BioWorld MedTech

Xencor unveils new programs targeting autoimmune and inflammatory diseases BioWorld MedTech

Xencor further shrinks oncology pipeline with pause on vudalimab - FirstWord Pharma

Xencor further shrinks oncology pipeline with pause on vudalimab FirstWord Pharma

Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline - Fierce Biotech

Roche drops HER2 bispecific, Xencor-partnered cytokine from early-phase pipeline Fierce Biotech

Xencor pulls back from Genentech cancer pact to cut costs as CytomX drops ex-AbbVie ADC - Fierce Biotech

Xencor pulls back from Genentech cancer pact to cut costs as CytomX drops ex-AbbVie ADC Fierce Biotech

Combining computational and experimental screening for rapid optimization of protein properties - PNAS

Combining computational and experimental screening for rapid optimization of protein properties PNAS

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy - Frontiers

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy Frontiers

Genentech pays Xencor $120M for rights to IL-15 cancer pipeline - Fierce Biotech

Genentech pays Xencor $120M for rights to IL-15 cancer pipeline Fierce Biotech

Xencor To Present At Jefferies Global Conference; Webcast At 8:00 AM ET - RTTNews

Xencor To Present At Jefferies Global Conference; Webcast At 8:00 AM ET RTTNews

Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening - Wiley Online Library

Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening Wiley Online Library

Top Xencor Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant